{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:32Z","timestamp":1753891232185,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden understanding of Omicron subvariant infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A total of 244 individuals with Omicron subvariant (BA.2.76, <jats:italic>n<\/jats:italic>\u202f=\u202f158; BA.5.1, <jats:italic>n<\/jats:italic>\u202f=\u202f86) were included in the study. Demographic, clinical, and laboratory data of the study participants were collected and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>Patients infected with BA.5.1 exhibited a higher incidence of clinical symptoms like fatigue (25.58% vs. 2.53%, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), headache\/dizziness (12.79% vs. 4.43%, <jats:italic>p<\/jats:italic>\u202f=\u202f0.017), nausea\/vomiting (10.47% vs. 1.27%, <jats:italic>p<\/jats:italic>\u202f=\u202f0.002), viral loads and inflammatory factors, and shorter virus shedding time than those with BA.2.76. There are 28.1% patients reporting mild adverse events following Azvudine administration. After treatment, the levels of anti-SARS-CoV-2 IgG\/IgM, white blood cell, and lymphocyte obviously increased, while C-reactive protein, procalcitonin, and D-dimer reduced. Azvudine speeded up the time for virus clearance compared to control treatment (10 vs. 11\u202fdays, <jats:italic>p<\/jats:italic>\u202f=\u202f0.032). Low lymphocyte counts (odd ratio (OR)\u202f=\u202f0.607, <jats:italic>p<\/jats:italic>\u202f=\u202f0.001) and anti-SARS-CoV-2 IgG titer (OR\u202f=\u202f0.990, <jats:italic>p<\/jats:italic>\u202f=\u202f0.028) were the independent risk factors for long nucleic acid negativization duration after infection. Patients with pneumonia were often accompanied by dyspnea, fatigue and high level of D-dimer. Dyspnea (OR\u202f=\u202f10.176, <jats:italic>p<\/jats:italic>\u202f=\u202f0.019) could be used to identify the occurrence of pneumonia in patients infected with Omicron.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study demonstrated the difference in clinical and laboratory parameters between patients infected with Omicron BA.2.76 and BA.5.1, as well as the safety and efficacy of Azvudine therapy. Our study linked patient manifestations to Omicron subvariant, treatment, and clinical outcomes, which is conducive to healthcare providers\/policymakers to revise and implement appropriate countermeasures, facilitating appropriately advise for individuals with Omicron subvariant infections.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1511227","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:47:20Z","timestamp":1734504440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Wenfang","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"809244","DOI":"10.3389\/fimmu.2021.809244","article-title":"SARS-CoV-2 variants, vaccines, and host immunity","volume":"12","author":"Mistry","year":"2021","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 omicron variant","volume":"603","author":"Suzuki","year":"2022","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.15585\/mmwr.mm7137a4","article-title":"Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and Delta variant pandemic periods - United States, April 2020-June 2022","volume":"71","author":"Adjei","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e35261","DOI":"10.7759\/cureus.35261","article-title":"Clinical characteristics and outcomes of laboratory-confirmed SARS-CoV-2 cases infected with omicron subvariants and the XBB recombinant variant","volume":"15","author":"Karyakarte","year":"2023","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/INF.0000000000003894","article-title":"Comparison of clinical characteristics of children infected with coronavirus disease 2019 between omicron variant BA.5 and BA.1\/BA.2 in Japan","volume":"42","author":"Ikuse","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1038\/s41598-023-34712-9","article-title":"A retrospective analysis of clinical features of patients hospitalized with SARS-CoV-2 omicron variants BA.1 and BA.2","volume":"13","author":"Groza","year":"2023","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"199134","DOI":"10.1016\/j.virusres.2023.199134","article-title":"SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells","volume":"332","author":"Gori Savellini","year":"2023","journal-title":"Virus Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jobb.2023.01.002","article-title":"Evolutionary analysis of omicron variant BF.7 and BA.5.2 pandemic in China","volume":"5","author":"Sun","year":"2023","journal-title":"J Biosaf Biosecur"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.46234\/ccdcw2023.096","article-title":"A comparison of clinical characteristics of infections with SARS-CoV-2 omicron subvariants BF.7.14 and BA.5.2.48 - China, October-December 2022","volume":"5","author":"Huo","year":"2023","journal-title":"China CDC Wkly"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1021\/acs.jcim.2c01352","article-title":"Emerging dominant SARS-CoV-2 variants","volume":"63","author":"Chen","year":"2023","journal-title":"J Chem Inf Model"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e230653","DOI":"10.1148\/radiol.230653","article-title":"Comparison of clinical outcomes and imaging features in hospitalized patients with SARS-CoV-2 omicron subvariants","volume":"308","author":"Lee","year":"2023","journal-title":"Radiology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41392-023-01443-2","article-title":"Distinct and relatively mild clinical characteristics of SARS-CoV-2 BA.5 infections against BA.2","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.jinf.2023.01.015","article-title":"Comparison of the clinical and virological characteristics of SARS-CoV-2 omicron BA.1\/BA.2 and omicron BA.5 variants: a prospective cohort study","volume":"86","author":"Kang","year":"2023","journal-title":"J Infect"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41467-023-37051-5","article-title":"Association of SARS-CoV-2 BA.4\/BA.5 omicron lineages with immune escape and clinical outcome","volume":"14","author":"Lewnard","year":"2023","journal-title":"Nat Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","article-title":"Azvudine (FNC): a promising clinical candidate for COVID-19 treatment","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.xinn.2022.100321","article-title":"The first Chinese oral anti-COVID-19 drug Azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innovation"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clinthera.2024.07.009","article-title":"Cost-effectiveness of Azvudine for high-risk outpatients with mild-to-moderate coronavirus disease 2019 in China","volume":"46","author":"Yang","year":"2024","journal-title":"Clin Ther"},{"year":"2023","key":"ref18"},{"key":"ref19","first-page":"161","article-title":"National Health Commission and National Administration of Traditional Chinese Medicine. Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 9)","volume":"12","year":"2022","journal-title":"Chinese J Viral Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/joim.13372","article-title":"Immunity to SARS-CoV-2 induced by infection or vaccination","volume":"291","author":"Castro Dopico","year":"2022","journal-title":"J Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12985-024-02316-y","article-title":"Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2024","journal-title":"Virol J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1215916","DOI":"10.3389\/fmed.2023.1215916","article-title":"Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients","volume":"10","author":"de Souza","year":"2023","journal-title":"Front Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e20153","DOI":"10.1016\/j.heliyon.2023.e20153","article-title":"Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e28947","DOI":"10.1002\/jmv.28947","article-title":"Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study","volume":"95","author":"Yang","year":"2023","journal-title":"J Med Virol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e29007","DOI":"10.1002\/jmv.29007","article-title":"Azvudine therapy of common COVID-19 in hemodialysis patients","volume":"95","author":"Shang","year":"2023","journal-title":"J Med Virol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"988694","DOI":"10.3389\/fcimb.2022.988694","article-title":"The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in omicron-infected patients: a retrospective observational cohort study from recent regional outbreaks in China","volume":"12","author":"Li","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"814782","DOI":"10.3389\/fcimb.2022.814782","article-title":"Unvaccinated children are an important link in the transmission of SARS-CoV-2 Delta variant (B1.617.2): comparative clinical evidence from a recent community surge","volume":"12","author":"Li","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1032957","DOI":"10.3389\/fpubh.2022.1032957","article-title":"Association between immunity and viral shedding duration in non-severe SARS-CoV-2 omicron variant-infected patients","volume":"10","author":"He","year":"2022","journal-title":"Front Public Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3760\/cma.j.cn112140-20220623-00582","article-title":"Characteristics and related factors of viral nucleic acid negative conversion in children infected with omicron variant strain of SARS-CoV-2","volume":"60","author":"Yin","year":"2022","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e12967","DOI":"10.1111\/sji.12967","article-title":"Lymphopenia an important immunological abnormality in patients with COVID-19: possible mechanisms","volume":"93","author":"Jafarzadeh","year":"2021","journal-title":"Scand J Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"13951","DOI":"10.3390\/ijms232213951","article-title":"Adaptive immunity to viruses: what did we learn from SARS-CoV-2 infection?","volume":"23","author":"Valyi-Nagy","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jiph.2021.03.001","article-title":"Early prediction keys for COVID-19 cases progression: a meta-analysis","volume":"14","author":"Khodeir","year":"2021","journal-title":"J Infect Public Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.imlet.2021.01.001","article-title":"Immune reactivity during COVID-19: implications for treatment","volume":"231","author":"Napoli","year":"2021","journal-title":"Immunol Lett"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e2199","DOI":"10.1002\/rmv.2199","article-title":"Immunity and inflammatory biomarkers in COVID-19: a systematic review","volume":"31","author":"Iwamura","year":"2021","journal-title":"Rev Med Virol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e28428","DOI":"10.1002\/jmv.28428","article-title":"Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV","volume":"95","author":"Zhan","year":"2023","journal-title":"J Med Virol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1511227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:47:23Z","timestamp":1734504443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1511227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":36,"alternative-id":["10.3389\/fmed.2024.1511227"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1511227","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1511227"}}